Skip to main content

Jonathan Serody, MD

Elizabeth Thomas Professor of Medicine, Microbiology and Immunology;
Chief Division of Hematology in the Department of Medicine;
Director of the Cellular Therapy Program
Associate Director of Translational Science UNC Lineberger Comprehensive Cancer Center
Co-leader Immunology Program UNC Lineberger Comprehensive Cancer Center

Specialty Areas

Bone Marrow Transplant; Adoptive Cellular Therapy focusing on Chimeric Antigen Receptor-modified T cells; Transplantation Immunology focused on the biology and treatment of graft-versus-host disease; Innate Lymphoid Cell development after allogeneic stem cell transplantation; Tumor Immunology focused on characterizing the tumor microenvironment in epithelial cancers

Chronology

  Degree   Institution   Area
  BA  University of Virginia  Biology
  MD  University of Virginia  Medicine
  Internship/Residency  University of North Carolina  Internal Medicine
  Fellowship  University of North Carolina  Infectious Disease/Hematology
  Fellowship Fred Hutchinson Cancer Research Center  Oncology/Bone Marrow Transplantation

Research and Clinical Interests

Dr. Serody is a hematologist specializing in the treatment of patients with leukemia, lymphoma and multiple myeloma who undergo therapy with stem cell transplantation or adoptive cellular therapy.  Since 2015, Dr. Serody has led the Immunotherapy Program at UNC-Lineberger Comprehensive Cancer Center focused on the use of a patient’s modified immune cells to treat cancer.  He has been the Medical Director for the Adoptive Cellular Therapy Facility which he helped design.  This research program has developed a therapy targeting CD30 that has shown substantial activity in the treatment of patients with Hodgkin lymphoma.  Additionally, his group was the first to demonstrate that the migration of donor white cells was important in the biology of acute graft-versus-host disease.  This work has led to the development of maraviroc, vedolizumab and fingolimid in the prevention and/or treatment of acute GVHD.  He serves as a consulting editor for the Journal of Clinical Investigation and was a previous editorial board member of Blood and the Journal of Clinical Oncology.

Personal Statement

I am a physician scientist with a focus on understanding how to use the immune system to treat cancer.  My group has been at the forefront of trying to understand how the immune system recognizes cancer cells and ways to improve this.  My clinical research has focused on a better understanding of the role of the immune system in the deleterious complication of acute GvHD in patients undergoing allogeneic stem cell transplantation and in the anti-tumor immune response.  Our group has generated vaccines, altered immune cells and new approaches to use the immune system to treat cancer.  I am deeply committed to improving patient outcomes through novel clinical trials and safer, more effective forms of therapy.  I work with a highly diverse, extremely sophisticated group of physicians, applied practice professionals, certified professional pharmacists, navigators, transplant coordinators, research coordinators, schedulers and I greatly value their input and the roles they play in holistic patient care.

Awards and Honors
1987 Outstanding Intern University of North Carolina Hospitals
1997-01 Member Scientific Review Group Subcommittee D for the National Cancer Institute
2000-2002 Member Parent Committee National Cancer Institute Scientific Review – Group Subcommittee D
2001-2004 Scientific Subcommittee on Transplantation Biology
2004-2007 Member SPORE Parent Committee
2005-2013 Standing member Leukemia and Lymphoma Society TRP Grant Review
2007-2010 Standing Member TTT Study Section
2011 Presidential Symposium Address American Association for Immunology
2016 Vice Chair Committee on Immunology and Host Defense American Society of Hematology
2017 Chairperson Committee on Immunology and Host Defense American Society of Hematology

 

View Publications